Back

Biogaran v. H. Lundbeck A/S, UPC Central Division, Milan section, 9 October 2026, Case no. UPC_CFI_1587/2025 

The Unified Patent Court (UPC) has delivered an important decision for pharmaceutical patentees and companies developing personalised medicine strategies. In Biogaran v. H. Lundbeck A/S, the Milan Central Division rejected a revocation action against a patent relating to the use of nalmefene for reducing alcohol consumption in a specifically defined subgroup of alcohol-dependent patients.  

We would particularly note that in this case the UPC confirmed that: 

  • A second medical use claim directed to a patient subgroup can be novel where the subgroup is physiologically or pathologically distinct and linked to a different therapeutic effect.  
  • An added matter attack must be pleaded with specificity. A mere assertion that a parent application contains many possible combinations will not suffice to make out the attack.  
  • Obviousness attacks built from large mosaics of prior art may be viewed as evidence of hindsight.  

We would also observe that the UPC validity analysis was based on the “problem-and-solution” approach of the European Patent Office (EPO). Thus this supports the view that UPC jurisprudence continues to develop in close alignment with established EPO principles. However, we have seen contrasts in jurisprudence between different UPC central divisions.  

This notwithstanding, for life sciences patentees, the decision provides valuable guidance on drafting and defending treatment claims based on particular patient subgroups. 

Overview of the Proceedings 

European patent EP 4 223 296, owned by H. Lundbeck A/S, concerns the use of nalmefene in reducing alcohol consumption in a particular subgroup of alcohol-dependent patients. The invention was not directed to nalmefene itself, nor to the general use of nalmefene in alcohol dependence, both of which were already known. Instead, the patent sought protection for the identification of patients who were particularly responsive to treatment.  

The revocation action was brought by Biogaran, which challenged the patent on the grounds of added matter, insufficiency, lack of novelty, lack of inventive step and invalid priority. The challenge failed in its entirety and the patent was maintained in amended form after deletion of two dependent claims.  

Added Matter: Specificity Matters 

One of the more significant procedural aspects of the judgment concerned the UPC’s treatment of added matter attacks. 

The claimant argued that the parent application contained numerous embodiments capable of generating millions of possible combinations and that the patent therefore impermissibly selected subject matter from that disclosure. The Court rejected this approach.  

The Court held that a party alleging added matter must identify, through a specific comparison, exactly what subject matter has allegedly been added. Merely pointing to a large number of potential combinations in a parent application is insufficient. An extension of subject matter arises only if the granted claim conveys technical information that the skilled person could not derive directly and unambiguously from the original disclosure.  

Particularly noteworthy was the Court’s statement that it would not develop an inadequately pleaded case on behalf of a revocation claimant. Doing so would constitute an impermissible ex officio investigation and would compromise judicial impartiality.  

This approach is likely to be welcomed by patentees facing broad-brush added matter attacks and reinforces the UPC’s front-loaded procedural model. 

Novelty of Patient Subgroup Claims 

The most important aspect of the decision is likely to be the Court’s analysis of novelty. 

The UPC accepted that novelty for a second medical use claim can arise from the identification of a patient subgroup, but only where the subgroup represents a physiologically or pathologically distinct group rather than an arbitrarily selected subset of a previously known population.  

The patented subgroup consisted of alcohol-dependent patients: 

  • who had a high drinking risk level (DRL); and 
  • who maintained that high drinking risk level after an observation period, 

thereby excluding “early reducers” who spontaneously improved before treatment commenced.  

The Court found that this subgroup had a meaningful clinical identity because evidence in the patent showed that nalmefene produced a more pronounced therapeutic effect in those patients than in broader patient populations. Importantly, the prior art failed to disclose either the same patient subgroup or the therapeutic significance of that subgroup. Accordingly, novelty was established.  

This reasoning may prove influential in future UPC cases involving biomarkers, responder populations, stratified medicine and precision medicine inventions. 

Sufficiency and Personalised Medicine 

The Court also adopted a patentee-friendly approach to sufficiency. 

The revocation claimant argued that the patent did not adequately explain how to identify the relevant patient subgroup and did not define the appropriate dosage with sufficient precision. The UPC disagreed.  

The Court held that where the invention lies in identifying a distinct patient subgroup, the patent must provide sufficient technical information to identify that subgroup and render the therapeutic effect credible for that subgroup. However, the precise therapeutic dosage need not necessarily appear in the independent claim if the skilled person can determine an appropriate dose using common general knowledge and routine experimentation.  

In reaching this conclusion, the Court drew heavily on sufficiency principles that are familiar from EPO practice.  

Inventive Step and Hindsight 

The inventive step analysis is also noteworthy. 

The Court formulated the objective technical problem as identifying the subgroup of alcohol-dependent patients who derive improved therapeutic benefit from nalmefene treatment.  

The claimant’s obviousness attack required the combination of numerous prior art disclosures relating to different technical issues. The Court considered this a textbook example of hindsight. It emphasised that separate disclosures cannot simply be combined because they could have been combined. There must be a pointer that would have led the skilled person to make the combination at the priority date.  

The Court went further, observing that where an inventive step attack requires the selection and combination of more than ten separate disclosures, none of which provides the missing motivation, the resulting mosaic is likely to be evidence of an ex post facto analysis rather than the path the skilled person would realistically have followed.  

This appears to be one of the strongest rebuttals to hindsight-driven obviousness attacks provided by a UPC court. 

Alignment with EPO Practice 

A recurring theme throughout the judgment is the Court’s use of principles already familiar to European patent practitioners. 

The decision repeatedly applies concepts such as: 

  • direct and unambiguous disclosure for added matter; 
  • credibility of therapeutic effects; 
  • novelty of second medical use claims; 
  • problem-and-solution style inventive-step reasoning.  

The judgment appears to show that UPC jurisprudence is evolving with reference to the EPC and EPO practice. However, as noted above, this would appear to contrast with the other UPC central divisions. This may reflect a case-driven approach where for example, the UPC may use the problem-and-solution approach, but is free to take a different approach if it better suits the circumstances of the case.  

Conclusion  

Thus Biogaran v. H. Lundbeck appears to be one of the more significant UPC decisions to date on the validity of pharmaceuticals. It thus provides useful guidance on subgroup-based second medical use claims. It also provides a lesson that the UPC approach is intended procedurally rigorous while building on principles established under the EPC. Thus this decision may become a leading authority on patient subgroup inventions, precision medicine claims, sufficiency in therapeutic inventions, and prevention of hindsight in inventive step analysis.  

Thus, for applicants, patentees, and life sciences companies, the decision provides several practical lessons, including: 

 

  • Define patient subgroups in clinically meaningful terms 
    • Patient subgroup claims are more likely to succeed where the distinguishing features reflect a genuine physiological or pathological distinction rather than an arbitrary selection from a known population.  
  • Explain in the specification why the patient subgroup matters 
    • Patent specifications should clearly explain why the identified subgroup responds differently to treatment and should include supporting clinical or mechanistic evidence wherever possible.  
  • Anticipate added matter challenges during drafting 
    • Where inventions rely on combinations of features drawn from multiple embodiments, the application should make those combinations explicit and clearly linked in the original disclosure.  
  • UPC proceedings are “front-loaded” 
    • UPC proceedings are “front-loaded” so cases and argumentation should be fully argued from the outset with any supporting documentation or evidence required. We see that the Milan Central Division was willing to exclude late-filed evidence and arguments. 

Our articles are for general information only. They should not be considered specific legal advice, which is available upon request. All information in our articles is considered to be accurate at the date of publishing.

Latest Firm News